APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT07492134
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Uncomplicated Diverticulitis

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet — DRUG
    amoxicillin-clavulanate:1 tablet \[875 mg amoxicillin; 125 mg clavulanic acid\] every 8 hours
  • Placebo — DRUG
    A placebo matching the antibiotic arm's treatment regimen will be administered for 10 days
  • Metronidazole — DRUG
    metronidazole: 500 mg every 12 hours
  • Cefuroxime — DRUG
    cefuroxime: 500 mg every 12 hours

Study Details

The goal of this clinical trial is to determine whether antibiotics improve recovery from acute uncomplicated diverticulitis (AUD) in racially and ethnically diverse United States clinical practice. The main questions it seeks to answer are: * What is the feasibility for completing a subsequent definitive efficacy trial of antibiotics vs. placebo to treat AUD? * What are the needs for successful recruitment of racial and ethnic subgroups? * What are the effects of a placebo compared to antibiotics for AUD on a range of key patient-centric efficacy and safety endpoints? * How do such effects differ by race and ethnicity? Researchers will compare a placebo to antibiotics to see if AUD can be treated without using antibiotics. Participants will: * Take two antibiotics or a matching placebo every day for 10 days * Receive analgesia, gastric protection, diet modifications, and a follow-up * Submit daily photos of pills to the study team to verify adherence

Key Dates

Start date
Apr 1, 2026
Status verified
Apr 2026
Primary completion
Apr 1, 2028
Completion
Oct 1, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Antibiotic
    The primary antibiotic choice will be amoxicillin-clavulanate (1 tablet \[875 mg amoxicillin; 125 mg clavulanic acid\] every 8 hours). If the subject has an allergy or contraindication to the primary antibiotic, we will administer cefuroxime \[500 mg\] every 12 hours plus metronidazole \[500 mg\] every 12 hours.
  • Experimental: Placebo
    A placebo matching the antibiotic arm's treatment regimen will be administered for 10 days

Primary Outcome Measure

Recruitment Rate [ Time Frame: From enrollment through study completion, an average of 2 years. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Vanderbilt University Medical Center Emergency DepartmentNashvilleTennessee37235
Alexander T Hawkins, MD, MPH
+1 (615)343-4612

Find similar trials in Nashville, TN

Related Studies